Aktie A092040 AMICOGEN, INC.
Zu einer Liste hinzufügen
Um diese Funktionalität nutzen zu können, müssen Sie Mitglied sein
EinloggenRegistrieren

Andere Sprachen Amicogen, Inc.

Aktien

A092040

KR7092040005

A092040

Schlusskurs Korea S.E.
Andere Börsenplätze
 00:00:00 01.07.2024 		% 5 Tage % 1. Jan.
5 130 KRW +2,40 % Intraday Chart für Amicogen, Inc. -28,95 % -32,14 %
16.05. Amicogen, Inc. meldet Ergebnis für das erste Quartal bis zum 31. März 2024 CI
20.03. Amicogen, Inc. meldet Ergebnis für das am 31. Dezember 2023 endende Geschäftsjahr CI

Andere Sprachen

Suchen
Ergebnisse ansehen
Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!
100% kostenlose Registrierung
Bio-Works and Amicogen have concluded their technology transfer project.
Fonds Small & Midcaps : Poursuite du rattrapage des petites cap’
Amicogen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024
Amicogen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023
Amicogen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
Amicogen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023
Amicogen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023
Beyond Cells announced that it has received KRW 3 billion in funding from Amicogen, Inc.
Amicogen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022
Lysando Ag and Amicogen Inc. Sign General Development Agreement
Amicogen, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022
Amicogen, Inc. announced that it expects to receive KRW 40 billion in funding
Amicogen, Inc. announced that it expects to receive KRW 40 billion in funding
Amicogen, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2022
Amicogen, Inc. announced that it has received KRW 8.7 billion in funding
Amicogen, Inc. announced that it expects to receive KRW 8.7 billion in funding
Amicogen, Inc. Reports Earnings Results for the Full Year Ended December 31, 2021
Amicogen, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021
Amicogen, Inc. completed the acquisition of 30% stake in BIFIDO Co., Ltd from a group of shareholders.
Bio Works Technologies : Amicogen Inc enters into agreement to divest its ownership in Bio-Works
Keine Ergebnisse zu dieser Suche
Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Filter

Suchen

Datum der Veröffentlichung

Vom

Bis

  1. Börse
  2. Aktien
  3. A092040 Aktie
  4. Nachrichten Amicogen, Inc.
  5. Andere Sprachen